Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.29 HKD | -0.14% | +7.05% | +9.13% |
15/04 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
15/04 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.13% | 648M | |
+33.43% | 690B | |
+26.43% | 546B | |
-5.12% | 358B | |
+19.59% | 323B | |
+4.89% | 287B | |
+14.32% | 235B | |
+5.79% | 199B | |
-9.49% | 195B | |
+4.26% | 161B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- Ocumension Therapeutics : Doses First Patient in Phase III Trial of Eye Drops in China; Shares Jump 3%